Fingerprint
Dive into the research topics of 'Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study
Armando Santoro, Lorenza Rimassa, Ivan Borbath, Bruno Daniele, Stefania Salvagni, Jean Luc Van Laethem, Hans Van Vlierberghe, Jörg Trojan, Frank T. Kolligs, Alan Weiss, Steven Miles, Antonio Gasbarrini, Monica Lencioni, Luca Cicalese, Morris Sherman, Cesare Gridelli, Peter Buggisch, Guido Gerken, Roland M. Schmid, Corrado Boni
Research output: Contribution to journal › Article › peer-review
504
Scopus
citations